Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment

Bristol-Myers Squibb (NYSE:BMY) recently announced a significant partnership with BioNTech SE to co-develop and co-commercialize the bispecific antibody BNT327, targeting multiple solid tumor types. This collaboration, alongside the European Commission's approval of a new formulation of Opdivo® for subcutaneous administration, may have added weight to the company's 4% share price rise over the past week. These events occurred in a market environment that saw an overall climb of 2%, suggesting that the company's recent strategic moves in oncology contributed positively to its momentum.

You should learn about the 3 possible red flags we've spotted with Bristol-Myers Squibb.

We've found 20 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

The recent collaboration between Bristol-Myers Squibb and BioNTech SE is anticipated to bolster the company's growth narrative. This partnership, especially in the oncology field, aligns with Bristol-Myers Squibb's strategic focus on expanding market acceptance and obtaining international approvals for key products like Opdivo. This has the potential to enhance revenue, as evidenced by the recent share price uptick. Over the longer term, Bristol-Myers Squibb's total return, including dividends, was 22.55% in the year ending May 2025. When compared to the broader market performance over the past year, Bristol-Myers Squibb's return outpaced the US Pharmaceuticals industry, which declined by 10.3%.

Considering upcoming pipeline milestones and cost-saving initiatives, the company's partnership with BioNTech is expected to positively impact revenue and earnings forecasts. Analysts project earnings growth from US$5.42 billion to US$9.8 billion by 2028, despite a forecasted annual revenue decline of 5% over the next three years. The current price of US$47.57 shows a discount to the analyst consensus price target of US$57.20. Investors should evaluate these forecasts and assumptions in the context of Bristol-Myers Squibb's projected operational efficiencies and strategic initiatives.

Evaluate Bristol-Myers Squibb's historical performance by accessing our past performance report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com